WALTHAM, Mass., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that President and CEO, Robert Ward, will be presenting a company overview at the 17th Annual BIO CEO & Investor Conference on Monday, February 9th, 2015 at 5:00 p.m. Eastern Time at the Waldorf Astoria in New York City
The company presentation will be webcast live on the Company’s website at www.radiuspharm.com, where a replay will be available following the presentation.
About Radius Health
Radius Health, Inc. is a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. The company’s lead development candidate is the investigational drug abaloparatide for subcutaneous injection, currently in Phase 3 development for the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, including breast cancer brain metastases. www.radiuspharm.com
CONTACT: Investor Relations Barbara Ryan 203-274-2825 bryan@radiuspharm.com
Help employers find you! Check out all the jobs and post your resume.
